^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SEZ6-targeted antibody-drug conjugate

    Related drugs:
    8d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=60 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    11d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=50 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    13d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, AbbVie | N=27 --> 50
    Enrollment change • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    14d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=27 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    16d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, AbbVie
    New P2 trial • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    20d
    M24-633: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Participants with Previously Untreated Extensive Stage Small Cell Lung Cancer (2024-517490-24-00)
    P1/2, N=18, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P1/2 trial • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ABBV-706
    2ms
    A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=531, Not yet recruiting, AbbVie
    New P3 trial • Adverse events
    |
    topotecan • Zepzelca (lurbinectedin) • ABBV-706 • Calsed (amrubicin)
    3ms
    Expanded Access to ABBV-706 (clinicaltrials.gov)
    P=N/A, N=0, Available, AbbVie
    New trial
    |
    ABBV-706
    4ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    4ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Trial completion date: Sep 2031 --> May 2029
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    4ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
    Enrollment open • Phase classification • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    5ms
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
    Trial completion date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706